TW202241471A - 提高個體中NKp30陽性淋巴球的方法及其用途 - Google Patents

提高個體中NKp30陽性淋巴球的方法及其用途 Download PDF

Info

Publication number
TW202241471A
TW202241471A TW111100816A TW111100816A TW202241471A TW 202241471 A TW202241471 A TW 202241471A TW 111100816 A TW111100816 A TW 111100816A TW 111100816 A TW111100816 A TW 111100816A TW 202241471 A TW202241471 A TW 202241471A
Authority
TW
Taiwan
Prior art keywords
cancer
positive
individual
cells
increase
Prior art date
Application number
TW111100816A
Other languages
English (en)
Chinese (zh)
Inventor
克莉絲緹娜 寇索林
勞倫斯 特卡
安娜 薩爾柏格瓦德納
Original Assignee
美商盧比亞斯治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商盧比亞斯治療公司 filed Critical 美商盧比亞斯治療公司
Publication of TW202241471A publication Critical patent/TW202241471A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111100816A 2021-01-08 2022-01-07 提高個體中NKp30陽性淋巴球的方法及其用途 TW202241471A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135559P 2021-01-08 2021-01-08
US63/135,559 2021-01-08

Publications (1)

Publication Number Publication Date
TW202241471A true TW202241471A (zh) 2022-11-01

Family

ID=80448430

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111100816A TW202241471A (zh) 2021-01-08 2022-01-07 提高個體中NKp30陽性淋巴球的方法及其用途

Country Status (2)

Country Link
TW (1) TW202241471A (fr)
WO (1) WO2022150569A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
ATE157879T1 (de) 1991-06-14 1997-09-15 Europ Communities Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
DE69732225T2 (de) 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
US6495351B2 (en) 2000-02-08 2002-12-17 Gendel Limited Loading system and method for using the same
EP4119662A1 (fr) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Modification de protéine de cellules vivantes utilisant la sortase
US10471099B2 (en) 2013-05-10 2019-11-12 Whitehead Institute For Biomedical Research In vitro production of red blood cells with proteins comprising sortase recognition motifs
CA2930665A1 (fr) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthetique- recepteur
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10869898B2 (en) 2014-04-01 2020-12-22 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
CA3010510A1 (fr) 2016-01-11 2017-07-20 Rubius Therapeutics, Inc. Compositions et procedes associes a des systemes cellulaires therapeutiques multimodaux pour indications immunitaires
WO2019173798A1 (fr) 2018-03-08 2019-09-12 Rubius Therapeutics, Inc. Systèmes cellulaires thérapeutiques et méthodes de traitement du cancer et de maladies infectieuses
JP2022530130A (ja) 2019-04-26 2022-06-27 ルビウス セラピューティクス， インコーポレイテッド 除核赤血球細胞を含む緩衝組成物
SG11202111995TA (en) 2019-05-24 2021-12-30 Rubius Therapeutics Inc Methods of generating enucleated erythroid cells

Also Published As

Publication number Publication date
WO2022150569A1 (fr) 2022-07-14

Similar Documents

Publication Publication Date Title
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP7093302B2 (ja) がん適応症のためのマルチモーダル治療用細胞系に関連する組成物および方法
ES2746856T3 (es) Células asesinas naturales manipuladas y usos de las mismas
TWI752930B (zh) 抗原特異性ｔｃｒ的新生成
EP2041171B1 (fr) Etiquette epitopique pour des proteines de surface et leurs utilisations
KR20200140279A (ko) 암 및 감염성 질환을 치료하기 위한 치료 세포 시스템 및 방법
JP2018518974A (ja) キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
KR20210029707A (ko) 재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물
US20220089718A1 (en) Chimeric antigen receptors with modified linker domains and uses thereof
CA3056542A1 (fr) Procede
KR20200087133A (ko) 변형된 car-t
EP3833682B1 (fr) Compositions et procédés de module suicide
CN115243713A (zh) 用于递送修饰的淋巴细胞聚集体的方法和组合物
EP3891269A1 (fr) Cellules présentatrices d'antigène artificielles comprenant des molécules hla-e et hla-g et procédés d'utilisation
AU2019347873A1 (en) Immunoresponsive cells expressing dominant negative Fas and uses thereof
JP2021512637A (ja) サイクリンａ１特異的ｔ細胞受容体およびその使用
US20200190541A1 (en) Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
TW202241471A (zh) 提高個體中NKp30陽性淋巴球的方法及其用途
TW202304482A (zh) 於個體中增加nkg2d陽性淋巴球之方法及其用途
US20210293787A1 (en) Combined invasion and cytotoxicity assay using chemokine secreting target cells
JP2018042531A (ja) キメラ抗原受容体
TW202241470A (zh) 治療人類個體腫瘤之方法
TW202317179A (zh) 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
WO2017221850A1 (fr) Molécule adaptateur pour amélioration des fonctions de cellule t
JP2024073636A (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用